Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib + TAS-102 + SBRT for third-line advanced colorectal adenocarcinoma with multiple liver and/or lung metastases
ChiCTR2100052373Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Nanjing Medical University
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of regorafenib and trifluridine + tipiracil in colorectal adenocarcinoma, sponsored by The Second Affiliated Hospital of Nanjing Medical University. Primary endpoints: Maximum tolerated dose and Progression-free survival. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
regorafenibtrifluridine + tipiracil
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2100052373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052373.